

Translational Lung Cancer Research is indexed by PubMed

Melanie C. He, Grace S. Li

Translational Lung Cancer Research, Editorial Office, AME Publishing Company, Guangzhou 510220, China

Correspondence to: Melanie C. He. Science Editor, Translational Lung Cancer Research, Editorial Office, AME Publishing Company, Guangzhou 510220, China. Email: editor@tlcr.org.

Submitted Dec 31, 2014. Accepted for publication Dec 31, 2014.

doi: 10.3978/j.issn.2218-6751.2015.01.03

View this article at: <http://dx.doi.org/10.3978/j.issn.2218-6751.2015.01.03>

On the early morning of December 31, 2014, the good news from PubMed Central has flown through the Editorial Office: *Translational Lung Cancer Research (TLCR)* has passed the evaluation and is officially indexed by PubMed (*Figure 1*)! This is one more milestone for *TLCR* as an acknowledgment of its expansion and dedication to translational research of lung cancer and will tremendously advance its continued exploration in the field.

Founded in March 2012, *TLCR* has been dedicated to providing cutting-edge findings in the rapidly changing field of lung cancer, while providing practical up-to-date information on diagnosis, prevention, and treatment. The goal of the journal is to provide readers with new, well-constructed, informative, and educational information. The Editors-in-Chief are Professor Caicun Zhou from Shanghai Pulmonary Hospital, Professor Yong Song from the Nanjing General Hospital of Nanjing Military Command, and Professor Rafael Rosell from the Pangaea Biotech, Dexeus University Institute, Catalan Institute of Oncology.

Since November 2013, *TLCR* has been endorsed by Spanish Lung Cancer Group (SLCG) (1). In January 2014, a new office of *TLCR* was established in General Hospital of Nanjing Military Region, Nanjing, China (*Figure 2*).

Over the past three years, *TLCR* has published a totality of 16 issues, among which there are focused issues led by the international experts in the field of lung cancer, including Profs. Rafael Rosell, Robert Pirker, Heather Wakelee, Paul Van Schil and others (*Table 1*). By providing a comprehensive landscape of a specific topic, these focused issues were proved to be well-received with a unique structure and format allowing tremendous progress in our ongoing understanding and sharing of knowledge (*Table 2*).

Particularly, in 2013 Prof. Rafael Rosell and Dr. Niki



Figure 1 *Translational Lung Cancer Research (TLCR)*.



Figure 2 One scene of the *Translational Lung Cancer Research's (TLCR)* editorial office in Nanjing.

Karachaliou organized two focused issues on lung cancer in collaboration with the authors from different countries. The two issues cover the new approaches for screening and diagnosis, new target therapy, prognosis and predictive

Table 1 The focused issues published on *Translational Lung Cancer Research (TLCR)*

Volume	Focused Issue	Guest Editor(s)	Affiliation
Vol 2, No 2	Lung Cancer Issue	Rafael Rosell, Niki Karachaliou	Catalan Institute of Oncology, Head of Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain; Breakthrough Cancer Research Unit, Pangaea Biotech, Barcelona, Spain
Vol 2, No 3	Lung Cancer Issue	Rafael Rosell, Niki Karachaliou	Catalan Institute of Oncology, Head of Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain; Breakthrough Cancer Research Unit, Pangaea Biotech, Barcelona, Spain
Vol 2, No 5	Management of Early Stage Non-small Cell Lung Cancer	Heather Wakelee	Associate Professor of Medicine, Oncology Stanford University, Stanford Cancer Institute, Stanford, CA 94305, USA
Vol 3, No 1	Immunotherapy in Lung Cancer	Yasuhiko Nishioka	Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
Vol 3, No 2	10 th Congress of Spanish Lung Cancer Group	Rafael Rosell, Bartomeu Massuti, Niki Karachaliou	Director, Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Badalona, Barcelona, Spain & President, Molecular Oncology Research (MORE) Foundation, Barcelona, Spain; Head, Medical Oncology Service, Hospital General de Alicante, Alicante, Spain; Dr Rosell Oncology Institute, Barcelona, Spain
Vol 3, No 3	4 th European Lung Cancer Congress	Paul Van Schil	Department of Thoracic and Vascular Surgery, UZA/Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem (Antwerp), Belgium
Vol 3, No 5	14 th Central European Lung Cancer Congress	Robert Pirker, Caicun Zhou	Division of Oncology, Medical University of Vienna, Vienna, Austria; Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
Vol 3, No 6	Personalized Therapy in Lung Cancer	Na Zhang, Wen-Zhao Zhong, Yi-Long Wu	Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China

Table 2 The most viewed articles published on *Translational Lung Cancer Research (TLCR)*

Issue	Title	Authors	Affiliation	Page views
Vol 2, No 5	Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?	Tetsuya Mitsudomi	Department of Thoracic Surgery, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511, Japan	16,409
Vol 2, No 2	KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach	Cristóbal Belda-Iniesta	Medical Oncology Unit-Department of Translational Oncology, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046 Madrid (Spain)	5,366
Vol 2, No 1	Irreversible EGFR-TKIs: dreaming perfection	Federico Cappuzzo	Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100 Livorno, Italy	4,643
Vol 1, No 1	Angiogenesis in cancer: anti-VEGF escape mechanisms	Gerald W. Prager	Medical University of Vienna, Comprehensive Cancer Center Vienna, Department of Medicine I, Waehringer Guertel 18-20, AT-1090 Vienna, Austria	4,525
Vol 2, No 1	MET inhibition in lung cancer	Jessica Menis	Department of Oncology, A.O.U Santa Maria della Misericordia of Udine, Piazzale Santa Maria della Misericordia, 33100 Udine, Italy	3,747
Vol 2, No 2	Activated RET and ROS: two new driver mutations in lung adenocarcinoma	Juergen Wolf	Dep. I of Internal Medicine, University Hospital Cologne, Kerpener Straße 62, D-50937 Köln, Germany	3,233

Figure 3 Announcement of the special issue for Central European Lung Cancer Congress (CELCC).

Table 3 Upcoming issues of *Translational Lung Cancer Research (TLCR)*

Upcoming Issues	Guest Editor(s)	Affiliation
Focused Issue		
Molecular Genetics in Lung Cancer	Wendy Cooper	Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW 2050
Imaging and Radiotherapy in Lung Cancer	David Ball	Deputy Director of Radiation Oncology & Cancer Imaging, Chair of Lung Service, Peter MacCallum Cancer Centre, Melbourne, Australia
Novel Approaches to <i>In Vivo</i> Imaging of NSCLC	Nhan L. Tran	Division of Cancer and Cell Biology, The Translational Genomics Research Institute, Phoenix, Arizona, USA

Table 4 New Special Column to be launched in 2015

New Special Column	Section Editors	Affiliation
Controversies in Lung Cancer—Pros and Cons	Suresh Senan	Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
	Helmut H. Popper	Research Unit for Molecular Lung & Pleura Pathology, Institute of Pathology, Medical University of Graz, Graz, Austria

molecular markers and other advanced treatments. They were then delicately translated and made into a Chinese guidebook by Prof. Song Yong and his team to meet the need of a huge population of Chinese physicians, surgeons and healthcare workers.

This October, *TLCR* published a special issue dedicated to the 14th Central European Lung Cancer Conference (CELCC), guest-edited by Profs. Robert Pirker and Caicun Zhou. The issue was acclaimed for its great content and exquisite layout design on the CELCC congress in Vienna (2) (*Figure 3*).

Centering on the research highlights, the 2014

December issue of *TLCR* also provide profound discussions on the latest clinical research outcomes upon lung cancer recently presented at this year’s ASCO meeting.

To embrace the forthcoming 2015, *TLCR* is going to publish the following new focused issues and special column (*Tables 3,4*).

In the end, we would like to express our highest appreciation to the distinguished Editors-in-Chief and editorial board members, respectable authors and readers worldwide for their lasting support and contribution to *TLCR*. Thanks to your joint efforts, *TLCR* is finally indexed by PubMed on the last day of 2014 after its inclusion

by Medscape. With more confidence, *TLCR* is working hard toward a robust platform with increased impact for the education, communication and exploration of the international researchers and clinicians.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

Cite this article as: He MC, Li GS. *Translational Lung Cancer Research* is indexed by PubMed. *Transl Lung Cancer Res* 2015;4(1):1-4. doi: 10.3978/j.issn.2218-6751.2015.01.03

References

1. TLCR is endorsed by the Spanish Lung Cancer Group (SLCG): new horizons for strong academic collaboration in lung cancer. Available online: <http://www.tlcr.org/announcement/view/61>
2. Li G. Highlights in the 14th Central European Lung Cancer Conference (CELCC). *Transl Lung Cancer Res* 2014;3:414-9.